RBC Capital Reiterates Outperform on Acadia Pharmaceuticals (ACAD) Following R&D Day
Tweet Send to a Friend
RBC Capital analyst Brian Abrahams reiterated an Outperform rating and $38.00 price target on Acadia Pharmaceuticals (NASDAQ: ACAD).The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
